clinical trial · NCT07062354
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
SWOG Cancer Research Network·phase2·enrolling by invitation·n = 50
Head &Amp; Neck CancerHead &Amp; Neck Squamous Cell CarcinomaAmivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
brief summary
This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
started
Mar 25, 2026
primary completion
Oct 1, 2028
completion
Oct 1, 2029
last updated
Apr 9, 2026
detailed description
This study is being done to find out if adding amivantamab hyaluronidase to the usual chemotherapy treatment can improve the usual treatment for advanced head and neck cancers.
official title
A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol